Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High – Time to Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $49.33 and last traded at $48.07, with a volume of 55405 shares. The stock had previously closed at $48.15.

Analyst Ratings Changes

Several research firms have recently issued reports on KNSA. Canaccord Genuity Group assumed coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 price target for the company. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.29.

Kiniksa Pharmaceuticals International Stock Up 1.4%

The company has a 50-day moving average price of $45.40 and a 200-day moving average price of $41.77. The company has a market capitalization of $3.74 billion, a price-to-earnings ratio of 65.97 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 65.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.12) EPS. Equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Mark Ragosa sold 17,845 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the sale, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. This represents a 59.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barry D. Quart sold 12,528 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $45.27, for a total transaction of $567,142.56. Following the completion of the sale, the director owned 12,546 shares in the company, valued at approximately $567,957.42. The trade was a 49.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 48,605 shares of company stock valued at $2,122,646. Corporate insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership acquired a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at about $20,349,000. Qube Research & Technologies Ltd grew its position in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares in the last quarter. Rubric Capital Management LP grew its position in Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after buying an additional 526,567 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after acquiring an additional 447,536 shares during the period. Finally, Spruce Street Capital LP bought a new position in Kiniksa Pharmaceuticals International during the fourth quarter valued at about $17,943,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.